Advertisement

$ 2.73
09:02 01/28/2009
Change: +0.13 +4.76% | Volume: 1,900
Biotechnology
Biomedical Advanced Research and Development Authority (BARDA) Exercises $4.1 Million Fourth Option on Cleveland BioLabs Contract to Develop Radiation Countermeasure CBLB502
Jul 29, 2010 9:00AM
Cleveland BioLabs, Inc. today announced that the Biomedical Advanced Research and Development Authority of the Department of Health and Human Services exercised the $4...

Cleveland BioLabs Inc. (CBLI), Biotechnology

Biotechnology
Cleveland Biolabs' CBLB502 for Reducing the Risk of Death Following Total Body Irradiation During or After a Radiation Disaster Granted Fast Track Status From FDA
Jul 22, 2010 8:30AM
Cleveland BioLabs, Inc. today announced that CBLB502, a drug under development for the treatment of Acute Radiation Syndrome , has been granted Fast Track status by the ...

Cleveland BioLabs Inc. (CBLI), Biotechnology, Clinical Trials

Clinical Trials
Cleveland BioLabs Publishes New Study on Curaxins Indicating Potential Antiviral Applications
Jul 20, 2010 9:00AM
Cleveland BioLabs, Inc. today announced that a groundbreaking discovery regarding potential antiviral applications for the Company's Curaxin family of molecules was pre-...

Cleveland BioLabs Inc. (CBLI), Clinical Trials, Biotechnology


About IBT PR Center
The IBTAnnouncement Service helps investors discover the latest information reported by companies in which they are invested, including changes in voting rights, net asset values, and more.

advertisement

Popular Tags

advertisement